SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific ADC
SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific ADC